Half of patients who stopped MRD-guided maintenance in GEM2014MAIN remained progression-free at 7 years, as IMS 2026 also featured DREAMM-9, MIDAS, and novel bispecific data.
Commentary|Articles|March 28, 2015
The Results and Key Takeaways From GOG0213
Author(s)Robert L. Coleman, MD, FACOG, FACS
Robert L. Coleman, MD, FACOG, FACS, professor, The University of Texas MD Anderson Cancer Center, discusses the results and key takeaways from GOG0213.
Advertisement
Robert L. Coleman, MD, FACOG, FACS, professor, The University of Texas MD Anderson Cancer Center, discusses the results and key takeaways from GOG0213. This phase III trial compared carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary, and fallopian tube cancer.
<<<
Advertisement
Related to this article
A new IMS/IMWG consensus definition requires 5 years of treatment-free, MRD-negative remission before multiple myeloma can be called cured.
Dr Raj Singh previews key ASTRO 2026 data, from FMISO PET-guided de-escalation in HPV-positive head and neck cancer to SRS vs whole brain radiotherapy trials in brain metastases.
Mezigdomide plus elranatamab yielded a 100% ORR in MELT-MM, as other IMS 2026 abstracts covered cevostamab, anito-cel vs cilta-cel, and linvoseltamab in HR-SMM.
Preview the 2026 International Myeloma Society meeting: the IMS/IMWG cure consensus, plenary session phase 3 trials, and new bispecific/CAR T myeloma findings.
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
Results from the phase 3 MAVERICK trial (SWOG S1827) show MRI surveillance alone improved cognitive failure-free survival vs adding PCI in SCLC.
The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
IMS Day 1 Recap: Bispecific and CAR T Data Shape Myeloma Treatment
2
Rusfertide Receives NCCN Category 1 Designation in Polycythemia Vera
3
Global Experts Define Consensus Criteria for Cure in Multiple Myeloma
4
Life-Years Saved Captures Gains—and Gaps—in Blood Cancer Treatment
5